Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097555 | 0.97 | NPC1 (0.40) | NPC1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL13053215 | 0.95 | SMN1; SMN2 (0.34) | NPC1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL10097600 | 0.95 | SMN1; SMN2 (0.34) | NPC1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL14466312 | 0.93 | NPC1 (0.38) | NPC1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL10097507 | 0.92 | NPC1 (0.36) | NPC1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL13052768 | 0.92 | SMN1; SMN2 (0.36) | NPC1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL12950234 | 0.92 | NPC1 (0.37) | NPC1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL13051956 | 0.92 | NPC1 (0.35) | NPC1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL10097602 | 0.92 | NPC1 (0.35) | NPC1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL10097368 | 0.92 | RAB9A (0.39) | NPC1CYP1A2CYP2D6CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | NPC1 87/4885CYP1A2 3179/4885CYP2D6 4186/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | NPC1 514/4885CYP1A2 3228/4885CYP2D6 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.